Novumcella Building Exosome Expertise In Inflammatory Disorders
Executive Summary
Tokyo-based Novumcella Inc. is progressing several still preclinical stage assets derived from academic research, with a focus on the intractable inflammatory disease area, and is looking to secure new financing and partners as it considers an IPO down the road.